Regenerative Medicine Industry Overview

The global regenerative medicine market size was valued at USD 30.43 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 16.79% from 2024 to 2030.

Recent advancements in biological therapies have resulted in a gradual shift in preference toward personalized medicinal strategies over the conventional treatment approach. This has created opportunities for companies that are involved in the development of biological therapeutics. Furthermore, the rise in the incidence of degenerative disorders has led to an increase in focus on research to discover novel regenerative therapies.

Gather more insights about the market drivers, restrains and growth of the Regenerative Medicine Market

The COVID-19 outbreak has considerably impacted various markets, including the regenerative medicine and T-cell therapy manufacturing market. The SARS-CoV-2 coronavirus crisis has significantly affected the delivery of CAR T-cell therapies. This impact is not just limited to patient care. It has extended beyond patient care to administration, logistics, and limited healthcare resources. Several universities have slowed down clinical trial enrollment and other research activities. However, the market continues to expand as market players such as Novartis provide access to therapies like Athersys, Inc.’s MultiStem, which is a highly relevant COVID-19 therapy.

Furthermore, regenerative medicines have been identified to have the unique ability to alter the fundamental mechanisms of diseases. Regenerative therapies in trials provide promising solutions for specific chronic indications with unmet medical needs. In December 2021, Novartis announced the introduction of T-ChargeTM, a next-generation CAR-T platform that would be a beneficial tool for novel investigational CAR-T cell therapies.

Significant advancements in molecular medicines have resulted in the development of gene-based therapy, which uses targeted delivery of DNA as a medicine to fight against various disorders. Gene therapy has high potential in the treatment of cancer and diabetes type 1 2 through restoring gene function. Currently, gene-based therapies are used in the treatment of patients suffering from cancer, oncology, infectious diseases, cardiovascular disorders, monogenic diseases, genetic disorders, ophthalmological indications, and diseases of the central nervous system. These factors have contributed to the growth of the market.

In addition, a strong product pipeline in clinical trials and the presence of government private funding to support research are expected to drive market growth over the forecast period. The presence of highly efficient products such as grafts, tissue patches, ointments, and scaffolds has resulted in the development of regenerative medicines for use in dermatology as well as musculoskeletal treatments. Advancements in nanotechnology that have further improved the efficiency of these products are expected to significantly contribute to revenue generation.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global recombinant DNA technology market size was valued at USD 728.9 billion in 2023 and is projected to grow at a CAGR of 5.4% from 2024 to 2030.
• The global DNA diagnostics market size was estimated at USD 10.64 billion in 2023 and is projected to grow at a CAGR of 4.51% from 2024 to 2030.

Key Companies Market Share Insights

Companies in the regenerative medicine sector are deploying multifaceted strategies to stay competitive in a rapidly evolving market. First and foremost, research and development investments remain paramount, enabling companies to pioneer cutting-edge technologies and stay ahead of the curve. Establishing strategic partnerships and collaborations with academic institutions and other industry players facilitates knowledge exchange and accelerates innovation. Robust intellectual property portfolios safeguard unique approaches, granting a competitive edge. Additionally, companies are focusing on efficient regulatory navigation, ensuring timely approvals and market access. As the market expands, cultivating strong relationships with healthcare providers and institutions becomes pivotal for adoption. Finally, fostering patient awareness and education through targeted marketing initiatives is crucial for building trust and ensuring a broader acceptance of regenerative medicine solutions in the healthcare landscape.

• AstraZeneca plc
• Hoffmann-La Roche Ltd.
• Integra Lifesciences Corp.
• Astellas Pharma, Inc.
• Cook Biotech, Inc.
• Bayer AG
• Pfizer, Inc.
• Merck KGaA
• Abbott
• Vericel Corp.
• Novartis AG
• GlaxoSmithKline (GSK)

Recent Developments

In October 2023, Editas drug, Inc. stated that the FDA has given EDIT-301, a research-stage gene editing drug, Regenerative Medicine Advanced Therapy (RMAT) classification for the treatment of severe sickle cell disease (SCD). In October 2022, Astellas Pharma Inc. and Pantherna Therapeutics GmbH announced a technology evaluation agreement to develop mRNA-based regenerative medicine programs through direct reprogramming. Their collaborative effort aims to expand treatment options for diseases with high unmet medical needs by targeting new organs.

In July 2022, Mogrify Limited and Astellas Pharma Inc. announced a collaborative research agreement to develop regenerative medicine approaches for sensorineural hearing loss. Astellas Gene Therapies will fund the research and provide expertise in AAV-based genetic medicine, while Mogrify will leverage its bioinformatic platform for screening and validation to identify potential therapeutic factors. Their shared goal is to transform the lives of patients with hearing loss through innovative regenerative therapies.

In January 2022, Novartis unveiled a strategic collaboration with Alnylam to harness Alnylam's established siRNA technology in inhibiting a target identified at Novartis Institutes for BioMedical Research. By merging regenerative medicine principles with cutting-edge siRNA technology, both companies aim to create a potential treatment fostering the regrowth of functional liver cells, offering an alternative to transplantation for patients suffering from liver failure.

Order a free sample PDF of the Regenerative Medicine Market Intelligence Study, published by Grand View Research.